Skip to main content

ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯌꯔꯒꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯂꯁꯤꯡ ꯑꯗꯨ ꯀꯔꯤꯅꯣ? (ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔꯒꯤ ꯃꯈꯂꯁꯤꯡ) ꯃꯁꯤ ꯌꯥꯝꯅꯥ ꯂꯥꯏꯅꯥ ꯂꯧꯁꯤ꯫

ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯌꯔꯒꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯂꯁꯤꯡ ꯑꯗꯨ ꯀꯔꯤꯅꯣ? (ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔꯒꯤ ꯃꯈꯂꯁꯤꯡ) ꯃꯁꯤ ꯌꯥꯝꯅꯥ ꯂꯥꯏꯅꯥ ꯂꯧꯁꯤ꯫

ꯅꯍꯥꯛꯅꯥ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯂꯩꯔꯦ ꯍꯥꯌꯕꯥ ꯈꯪꯂꯕꯥ ꯃꯇꯃꯗꯥ ꯅꯍꯥꯛꯅꯥ ꯐꯥꯎꯔꯤꯕꯥ ꯑꯀꯤꯕꯥ ꯑꯃꯁꯨꯡ ꯁꯣꯀꯄꯥ ꯑꯗꯨ ꯋꯥꯍꯩꯅꯥ ꯐꯣꯡꯗꯣꯀꯄꯥ ꯌꯥꯝꯅꯥ ꯂꯨꯏ꯫ ꯑꯗꯣꯃꯒꯤ ꯋꯥꯈꯂꯗꯥ ꯋꯥꯍꯪ ꯀꯌꯥ ꯑꯃꯥ ꯂꯩꯔꯤ꯫ "ꯑꯩꯉꯣꯟꯗꯥ ꯀꯔꯤꯒꯤ ꯊꯣꯀꯈꯤꯕꯅꯣ?", "ꯍꯧꯖꯤꯛ ꯑꯩꯅꯥ ꯀꯔꯤ ꯇꯧꯔꯤꯕꯅꯣ?", "ꯃꯁꯤ ꯂꯥꯌꯦꯡꯕꯥ ꯉꯃꯒꯗ꯭ꯔꯥ?", ꯑꯁꯤꯒꯨꯝꯕꯥ ꯋꯥꯍꯪꯁꯤꯡ ꯑꯁꯤ ꯅꯣꯔꯃꯦꯂꯅꯤ꯫ ꯈꯣꯡꯆꯠ ꯑꯁꯤꯗꯥ ꯑꯩꯍꯥꯛꯅꯥ ꯋꯥꯐꯃꯁꯤꯡ ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯂꯥꯏꯅꯥ ꯑꯃꯁꯨꯡ ꯑꯗꯣꯝꯅꯥ ꯈꯉꯕꯥ ꯉꯝꯕꯥ ꯂꯣꯜ ꯑꯃꯗꯥ ꯐꯣꯡꯗꯣꯛꯅꯕꯥ ꯍꯣꯠꯅꯔꯤ꯫ ꯅꯍꯥꯛꯅꯥ ꯀꯔꯤ ꯃꯈꯂꯒꯤ ꯀꯦꯟꯁꯔ ꯂꯩꯕꯒꯦ ꯍꯥꯌꯕꯗꯨ ꯆꯨꯝꯅꯥ ꯈꯉꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯂꯥꯟ ꯍꯧꯗ꯭ꯔꯤꯉꯩꯒꯤ ꯃꯃꯥꯡꯗꯥ ꯌꯦꯛꯅꯕꯥ ꯑꯗꯨꯕꯨ ꯈꯉꯕꯒꯥ ꯃꯥꯟꯅꯩ꯫ ꯃꯗꯨ ꯅꯍꯥꯛꯀꯤꯗꯃꯛꯇꯥ ꯆꯨꯅꯕꯥ ꯂꯥꯏꯌꯦꯡ ꯈꯅꯕꯒꯤ ꯑꯍꯥꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯈꯣꯡꯊꯥꯡꯅꯤ꯫

ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ-ꯄꯣꯖꯤꯇꯤꯚ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ꯫

ꯃꯁꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯀꯃꯟ ꯑꯣꯏꯕꯥ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯃꯈꯜꯅꯤ꯫ ꯆꯥꯎꯔꯥꯛꯅꯥ ꯍꯥꯌꯔꯕꯗꯥ, ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ 100 ꯈꯨꯗꯤꯡꯒꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 80ꯗꯤ ꯀꯦꯇꯦꯒꯣꯔꯤ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡ ꯆꯜꯂꯤ꯫

ꯑꯗꯨꯅꯥ ꯃꯁꯤꯒꯤ "ꯍꯣꯔꯃꯣꯟ-ꯗꯤꯄꯦꯟꯗꯦꯟꯇ" ꯍꯥꯌꯕꯁꯤ ꯀꯔꯤꯅꯣ?

ꯃꯁꯤꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯁꯨꯞꯅꯇꯒꯤ ꯈꯟꯊꯕꯤꯌꯨ꯫ ꯑꯩꯈꯣꯌꯒꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯃꯔꯨꯑꯣꯏꯅꯥ ꯅꯨꯄꯤꯁꯤꯡꯒꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯃꯍꯧꯁꯥꯅꯥ ꯊꯣꯀꯄꯥ ꯍꯣꯔꯃꯣꯟ ꯑꯅꯤ ꯂꯩ, ꯃꯈꯣꯌꯁꯤꯡ ꯑꯗꯨꯗꯤ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯑꯃꯁꯨꯡ ꯄ꯭ꯔꯣꯖꯦꯁ꯭ꯇꯦꯔꯣꯟ . ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤ ꯑꯩꯈꯣꯌꯒꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯅꯣꯔꯃꯦꯜ ꯑꯣꯏꯕꯥ ꯊꯧꯑꯣꯡꯁꯤꯡꯒꯤꯗꯃꯛ ꯇꯉꯥꯏ ꯐꯗꯕꯁꯤꯡꯅꯤ꯫ ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯈꯔꯗꯤ ꯍꯣꯔꯃꯣꯅꯁꯤꯡ ꯑꯁꯤꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯌꯥꯝꯅꯥ "ꯑꯦꯗꯤꯛꯇ" ꯑꯣꯏ꯫ ꯍꯥꯌꯕꯗꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯁꯤꯒꯤ ꯃꯊꯛꯇꯥ, ꯍꯣꯔꯃꯣꯅꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯂꯥꯛꯇꯨꯅꯥ ꯂꯦꯞꯄꯥ ꯌꯥꯕꯥ "ꯔꯤꯁꯦꯄꯇꯔ" ꯅꯠꯠꯔꯒꯥ ꯊꯣꯡ ꯈꯔꯥ ꯂꯩ꯫ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯍꯣꯔꯃꯣꯟ ꯂꯥꯛꯇꯨꯅꯥ ꯊꯣꯡ ꯑꯗꯨꯗꯥ ꯊꯨꯒꯥꯌꯕꯥ ꯃꯇꯃꯗꯥ, ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯑꯗꯨꯅꯥ ꯃꯗꯨꯗꯒꯤ ꯃꯆꯤꯟꯖꯥꯛ ꯐꯪꯏ ꯑꯃꯁꯨꯡ ꯆꯥꯎꯈꯠꯄꯥ ꯑꯃꯁꯨꯡ ꯈꯥꯌꯗꯣꯀꯄꯥ ꯍꯧꯏ꯫ ꯄꯥꯝꯕꯤ ꯑꯃꯗꯥ ꯏꯁꯤꯡ ꯄꯤꯖꯕꯥ ꯃꯇꯃꯗꯥ ꯃꯗꯨꯁꯨ ꯍꯦꯟꯅꯥ ꯆꯥꯎꯈꯠꯂꯀꯏ꯫

ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯀꯤ ꯃꯦꯗꯤꯀꯦꯜ ꯔꯤꯄꯣꯔꯠ ꯑꯗꯨꯗꯥ `ER-positive` (Estrogen Receptor-Positive) ꯍꯥꯌꯔꯕꯗꯤ, ꯃꯁꯤꯅꯥ ꯅꯍꯥꯛꯀꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯗꯨ ꯍꯣꯔꯃꯣꯟ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯅꯗꯥ ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯣꯏ ꯍꯥꯌꯕꯅꯤ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯃꯁꯤꯅꯥ `PR-positive` (Progesterone Receptor-Positive) ꯍꯥꯌꯔꯕꯗꯤ, ꯃꯁꯤꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯄ꯭ꯔꯣꯖꯦꯁ꯭ꯇꯦꯔꯣꯅꯗꯥ ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯣꯏ ꯍꯥꯌꯕꯅꯤ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯃꯁꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯑꯃꯗꯥ ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯣꯏꯔꯕꯗꯤ, ꯀꯦꯟꯁꯔ ꯑꯗꯨꯕꯨ ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯞꯇꯔ-ꯄꯣꯖꯤꯇꯤꯚ ꯀꯦꯟꯁꯔ ꯍꯥꯌꯅꯥ ꯀꯧꯏ꯫

ꯃꯁꯤ ꯇꯁꯦꯡꯅꯥ ꯃꯑꯣꯡ ꯑꯃꯗꯥ ꯑꯐꯕꯥ ꯄꯥꯎꯅꯤ꯫ ꯃꯔꯃꯗꯤ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯩꯈꯣꯌꯅꯥ ꯀꯦꯟꯁꯔꯅꯥ ꯆꯥꯎꯈꯠꯄꯗꯥ ꯀꯔꯤ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯒꯦ ꯍꯥꯌꯕꯥ ꯈꯉꯂꯕꯗꯤ ꯑꯩꯈꯣꯌꯅꯥ ꯂꯝꯕꯤ ꯑꯗꯨ ꯕ꯭ꯂꯣꯛ ꯇꯧꯕꯥ ꯉꯃꯒꯅꯤ ꯑꯃꯁꯨꯡ ꯀꯦꯟꯁꯔ ꯑꯗꯨ ꯀꯟꯠꯔꯣꯜ ꯇꯧꯕꯥ ꯉꯃꯒꯅꯤ꯫ "ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤ" ꯍꯥꯌꯕꯁꯤ ꯃꯗꯨꯒꯤꯗꯃꯛꯇꯅꯤ꯫

ꯃꯍꯧꯁꯥꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤ ꯑꯁꯤ ꯁꯔꯖꯔꯤ, ꯀꯦꯃꯣꯊꯦꯔꯥꯄꯤ ꯅꯠꯠꯔꯒꯥ ꯔꯦꯗꯤꯑꯦꯁꯅꯒꯤ ꯃꯇꯨꯡꯗꯥ ꯀꯦꯟꯁꯔ ꯑꯗꯨ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯂꯥꯀꯄꯥ ꯊꯤꯡꯅꯕꯥ ꯄꯤ꯫ ꯍꯤꯗꯥꯀꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡꯗꯥ "ꯊꯣꯡ" ꯊꯤꯡꯗꯨꯅꯥ, ꯅꯠꯠꯔꯒꯥ ꯍꯀꯆꯥꯡꯅꯥ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯁꯦꯝꯕꯥ ꯊꯤꯡꯗꯨꯅꯥ ꯊꯕꯛ ꯇꯧꯏ꯫

ꯂꯥꯏꯌꯦꯡꯕꯒꯤ ꯀꯦꯇꯦꯒꯣꯔꯤ꯫ꯏꯆꯝ ꯆꯝꯕꯥ ꯃꯌꯦꯛ ꯁꯦꯡꯅꯥ ꯇꯥꯀꯄꯥ ꯑꯃꯁꯨꯡ ꯈꯨꯗꯃꯁꯤꯡ꯫
ꯑꯦꯁ.ꯏ.ꯑꯥꯔ.ꯑꯦꯝ.ꯁꯤꯡ (ꯁꯦꯂꯦꯛꯇꯤꯕ ꯏ.ꯑꯥꯔ. ꯃꯣꯗ꯭ꯌꯨꯂꯦꯇꯔꯁꯤꯡ) ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯗꯥ ꯂꯩꯕꯥ ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯗꯨ ꯕ꯭ꯂꯣꯛ ꯇꯧꯗꯨꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯑꯗꯨ ꯆꯪꯂꯀꯄꯥ ꯊꯤꯡꯏ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯇꯥꯃꯣꯛꯁꯤꯐꯦꯟ, ꯇꯣꯔꯦꯃꯤꯐꯦꯟ .
ꯑꯦꯁ.ꯏ.ꯑꯥꯔ.ꯗꯤ.ꯁꯤꯡ (ꯁꯦꯂꯦꯛꯇꯤꯕ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯔꯤꯁꯦꯄꯇꯔ ꯗꯤꯒ꯭ꯔꯦꯗꯔꯁꯤꯡ) ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯗꯨ ꯕ꯭ꯂꯣꯛ ꯇꯧꯕꯇꯥ ꯅꯠꯇꯅꯥ ꯃꯗꯨꯁꯨ ꯃꯥꯡꯍꯜꯂꯤ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯐꯨꯂꯚꯦꯁ꯭ꯠꯔꯦꯟꯇ (ꯐꯥꯁꯂꯣꯗꯦꯛꯁ), ꯏꯂꯥꯁꯦꯁ꯭ꯠꯔꯦꯟꯇ (ꯑꯣꯔꯁꯦꯔꯗꯨ) .
ꯑꯦꯔꯣꯃꯥꯇꯦꯖ ꯏꯅꯍꯤꯕꯤꯇꯔꯁꯤꯡ꯫ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯍꯀꯆꯥꯡꯗꯥ ꯍꯣꯔꯃꯣꯟ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ (ꯑꯌꯥꯝꯕꯥ ꯃꯇꯃꯗꯥ ꯄꯣꯁ꯭ꯠ-ꯃꯦꯅꯣꯄꯣꯖꯜ ꯅꯨꯄꯤꯁꯤꯡꯗꯥ ꯄꯤꯕꯥ) ꯄꯨꯊꯣꯀꯄꯥ ꯊꯤꯡꯏ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯑꯦꯅꯥꯁ꯭ꯠꯔꯣꯖꯣꯜ (ꯑꯦꯔꯤꯃꯤꯗꯦꯛꯁ), ꯂꯦꯠꯔꯣꯖꯣꯜ (ꯐꯦꯃꯥꯔꯥ) .
ꯑꯦꯜ.ꯑꯩꯆ.ꯑꯥꯔ.ꯑꯩꯆ.ꯒꯤ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯇꯁꯤꯡ꯫ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯃꯇꯝ ꯈꯔꯒꯤ ꯑꯣꯏꯅꯥ ꯑꯣꯚꯔꯑꯣꯜ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯄꯨꯊꯣꯀꯄꯥ ꯊꯤꯡꯏ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯒꯣꯁꯦꯔꯦꯂꯤꯟ (ꯖꯣꯂꯥꯗꯦꯛꯁ), ꯂꯤꯎꯞꯔꯣꯂꯥꯏꯗ (ꯂꯨꯞꯔꯣꯟ) .
ꯑꯇꯣꯞꯄꯥ ꯇꯥꯔꯒꯦꯠ ꯇꯧꯔꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ꯫ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤꯒꯤ ꯃꯥꯌ ꯄꯥꯀꯄꯥ ꯍꯦꯅꯒꯠꯍꯅꯕꯥ ꯑꯇꯣꯞꯄꯥ ꯗ꯭ꯔꯒꯁꯤꯡ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯄꯥꯂꯕꯣꯁꯤꯛꯂꯤꯕ (ꯏꯕ꯭ꯔꯥꯟꯁ), ꯔꯥꯏꯕꯣꯁꯤꯛꯂꯤꯕ (ꯀꯤꯁꯀꯥꯂꯤ), ꯑꯂꯄꯦꯂꯤꯁꯤꯕ (ꯄꯤꯛꯔꯦ) .

HER2-ꯄꯣꯖꯤꯇꯤꯚ ꯑꯣꯏꯕꯥ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ꯫

ꯍꯧꯖꯤꯛ ꯑꯇꯣꯞꯄꯥ ꯃꯈꯜ ꯑꯃꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯋꯥꯔꯤ ꯁꯥꯔꯁꯤ꯫ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯈꯔꯗꯤ (ꯀꯦꯟꯁꯔ ꯄꯨꯝꯅꯃꯛꯀꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 20%)ꯅꯥ ꯃꯈꯣꯌꯒꯤ ꯃꯊꯛꯇꯥ HER2 (Human Epidermal growth factor Receptor 2) ꯀꯧꯕꯥ ꯑꯈꯟꯅꯕꯥ ꯄ꯭ꯔꯣꯇꯤꯟ ꯑꯃꯥ ꯌꯥꯝꯅꯥ ꯄꯨꯊꯣꯀꯏ꯫

HER2 ꯑꯁꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯗꯥ "ꯌꯥꯝꯅꯥ ꯌꯥꯡꯅꯥ ꯆꯥꯎꯈꯠꯄꯥ, ꯌꯥꯡꯅꯥ ꯈꯥꯌꯗꯣꯀꯄꯥ" ꯍꯥꯌꯕꯥ ꯈꯔꯥ ꯑꯦꯟꯇꯦꯅꯥ ꯑꯃꯥ ꯑꯣꯏꯅꯥ ꯈꯅꯕꯤꯌꯨ꯫ ꯅꯣꯔꯃꯦꯜ ꯁꯦꯜ ꯑꯃꯗꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯑꯦꯟꯇꯦꯅꯥꯁꯤꯡ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯈꯔꯈꯛꯇꯃꯛ ꯂꯩ꯫ ꯑꯗꯨꯕꯨ HER2 ꯄꯣꯖꯤꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯑꯃꯗꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯑꯦꯟꯇꯦꯅꯥ ꯀꯌꯥ ꯑꯃꯥ ꯂꯩ꯫ ꯃꯔꯝ ꯑꯁꯤꯅꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯃꯈꯂꯒꯤ ꯀꯦꯟꯁꯔꯁꯤꯡ ꯑꯁꯤ ꯍꯦꯟꯅꯥ ꯑꯦꯒ꯭ꯔꯦꯁꯤꯕ ꯑꯣꯏꯕꯥ ꯌꯥꯏ .

ꯑꯗꯨꯕꯨ ꯃꯐꯝ ꯑꯁꯤꯗꯥ ꯑꯐꯕꯥ ꯄꯥꯎ ꯑꯃꯁꯨ ꯂꯩꯔꯤ꯫ ꯁꯥꯏꯟꯁꯇꯥ ꯑꯍꯣꯡꯕꯥ ꯂꯥꯀꯄꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯍꯧꯖꯤꯛꯇꯤ ꯌꯥꯝꯅꯥ HER2 ꯑꯦꯟꯇꯦꯅꯥꯁꯤꯡ ꯑꯁꯤꯕꯨ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤꯕꯥ ꯑꯃꯁꯨꯡ ꯃꯥꯡꯍꯅꯕꯥ ꯉꯝꯕꯥ "ꯇꯥꯔꯒꯦꯠ ꯇꯧꯔꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ " ꯂꯩꯔꯦ꯫ ꯃꯔꯃꯗꯤ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ HER2 ꯌꯥꯝꯅꯥ ꯂꯩꯕꯥ ꯁꯦꯂꯁꯤꯡꯈꯛꯇꯗꯥ ꯊꯤꯗꯨꯅꯥ ꯑꯦꯇꯦꯛ ꯇꯧꯏ, ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯅꯣꯔꯃꯦꯜ ꯁꯦꯂꯁꯤꯡꯗꯥ ꯑꯃꯥꯡ-ꯑꯇꯥ ꯍꯟꯊꯍꯜꯂꯤ꯫

ꯃꯁꯤꯒꯤꯗꯃꯛꯇꯥ ꯄꯤꯔꯤꯕꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯑꯃꯁꯨꯡ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯏꯐꯦꯛꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯗ꯭ꯔꯒ ꯑꯁꯤ ꯇ꯭ꯔꯥꯁ꯭ꯇꯨꯖꯨꯃꯕ (Herceptin) . ꯃꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯑꯗꯨ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯂꯥꯀꯄꯥ ꯊꯤꯡꯕꯗꯥ ꯌꯥꯝꯅꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫ ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯂꯥꯏꯌꯦꯡ ꯑꯁꯤ ꯂꯧꯕꯥ ꯃꯇꯃꯗꯥ ꯍꯥꯔꯠ ꯅꯠꯠꯔꯒꯥ ꯂꯪꯁꯇꯥ ꯏꯐꯦꯛꯇ ꯈꯔꯒꯤ ꯔꯤꯁ꯭ꯛ ꯂꯩ꯫ ꯃꯗꯨꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯋꯥꯈꯜ ꯋꯥꯕꯥ ꯂꯩꯔꯣꯏꯗꯕꯅꯤ , ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯅꯥ ꯃꯇꯝ ꯄꯨꯝꯅꯃꯛꯇꯥ ꯃꯁꯤꯒꯤꯗꯃꯛꯇꯥ ꯆꯦꯛ ꯇꯧꯒꯅꯤ꯫

ꯍꯦꯔ꯲-ꯄꯣꯖꯤꯇꯤꯕ ꯀꯦꯟꯁꯔꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯥ ꯑꯇꯣꯞꯄꯥ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ꯫
ꯄꯦꯔꯇꯨꯖꯨꯃꯕ (ꯄꯦꯔꯖꯦꯇꯥ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ. ꯑꯦꯗꯣ-ꯇ꯭ꯔꯥꯁ꯭ꯇꯨꯖꯨꯃꯕ ꯏꯃꯇꯥꯅꯁꯤꯟ (ꯀꯗꯁꯤꯂꯥ) ꯑꯁꯤ ꯑꯦꯟ.
ꯂꯥꯄꯥꯇꯤꯅꯤꯕ (ꯇꯥꯏꯀꯦꯔꯕ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ. ꯅꯦꯔꯥꯇꯤꯅꯤꯕ (ꯅꯦꯔꯂꯤꯅꯛꯁ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ.
ꯇꯨꯀꯥꯇꯤꯅꯤꯕ (ꯇꯨꯀꯤꯁꯥ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ. ꯑꯦꯅꯍꯦꯔꯇꯨ (Fam-trastuzumab deruxtecan-nxki) ꯑꯁꯤꯅꯆꯤꯡꯕꯥ (Fam-trastuzumab deruxtecan-nxki)

"ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ" ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ꯫

ꯃꯁꯤ ꯑꯍꯨꯃꯁꯨꯕꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯂꯅꯤ꯫ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔꯒꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 10%-20%ꯗꯤ ꯃꯈꯜ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡ ꯆꯜꯂꯤ꯫ ꯀꯔꯤꯒꯤꯗꯃꯛꯇꯥ ꯃꯁꯤꯕꯨ "ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ" ꯅꯠꯔꯒꯥ "ꯇ꯭ꯔꯤꯄꯜ ꯅꯦꯒꯦꯇꯤꯕ" ꯍꯥꯌꯅꯥ ꯀꯧꯔꯤꯕꯅꯣ ꯍꯥꯌꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯈꯉꯕ꯭ꯔꯥ?

ꯃꯔꯃꯗꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯁꯤꯗꯥ , .

꯱.ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯔꯤꯁꯦꯄꯇꯔ (ꯏ.ꯇꯤ.ꯌꯨ.) ꯂꯩꯇꯕꯥ .

2. ꯄ꯭ꯔꯣꯖꯦꯁ꯭ꯇꯦꯔꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ (PR) ꯂꯩꯇꯕꯥ꯫

3. HER2 ꯄ꯭ꯔꯣꯇꯤꯟ ꯌꯥꯝꯅꯥ ꯂꯩꯇꯦ꯫

ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯑꯩꯈꯣꯌꯅꯥ ꯃꯃꯥꯡꯗꯥ ꯈꯟꯅꯈꯤꯕꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯄꯥꯟꯗꯝ ꯑꯍꯨꯝ ꯑꯁꯤ ꯂꯩꯇꯕꯅꯥ ꯃꯔꯝ ꯑꯣꯏꯗꯨꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤ ꯅꯠꯔꯒꯥ ꯍꯔꯁꯦꯞꯇꯤꯅꯒꯨꯝꯕꯥ HER2-ꯇꯥꯔꯒꯦꯠ ꯇꯧꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡꯅꯥ ꯃꯈꯣꯌꯗꯥ ꯊꯕꯛ ꯇꯧꯗꯦ꯫ ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯃꯈꯣꯌꯕꯨ ꯂꯥꯌꯦꯡꯕꯗꯥ ꯈꯔꯥ ꯁꯤꯡꯅꯕꯥ ꯑꯃꯥ ꯑꯣꯏꯕꯥ ꯌꯥꯏ꯫

ꯀꯦꯟꯁꯔ ꯃꯈꯜ ꯑꯁꯤ ꯑꯌꯥꯝꯕꯅꯥ ꯕꯤ.ꯑꯥꯔ.ꯁꯤ.ꯑꯦ.꯱ꯅꯥ ꯊꯣꯀꯍꯜꯂꯤ꯫ꯃꯁꯤ ꯖꯤꯟ ꯑꯃꯗꯥ ꯃ꯭ꯌꯨꯇꯦꯁꯟ ꯑꯃꯒꯥ ꯃꯔꯤ ꯂꯩꯅꯩ . ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯚ ꯀꯦꯟꯁꯔ ꯂꯩꯔꯕꯗꯤ, ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯅꯥ ꯖꯦꯅꯦꯇꯤꯛ ꯇꯦꯁ꯭ꯠ ꯇꯧꯅꯕꯥ ꯄꯥꯎꯇꯥꯛ ꯄꯤꯕꯁꯨ ꯌꯥꯏ꯫

ꯃꯁꯤꯒꯤ ꯃꯈꯜ ꯑꯁꯤ ꯃꯔꯨꯑꯣꯏꯅꯥ ꯁꯔꯖꯔꯤ, ꯀꯦꯃꯣꯊꯦꯔꯥꯄꯤ, ꯑꯃꯁꯨꯡ ꯔꯦꯗꯤꯑꯦꯁꯅꯅꯥ ꯂꯥꯌꯦꯡꯏ . ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯍꯧꯖꯤꯛꯇꯤ ꯃꯈꯜ ꯑꯁꯤꯒꯤ ꯑꯀꯛꯅꯕꯥ ꯑꯅꯧꯕꯥ ꯂꯥꯌꯦꯡꯁꯤꯡ ꯂꯩꯔꯦ꯫

  • ꯄꯤ.ꯑꯦ.ꯑꯥꯔ.ꯄꯤ.ꯒꯤ ꯏꯅꯍꯤꯕꯤꯇꯔꯁꯤꯡ: ꯑꯣꯂꯥꯄꯥꯔꯤꯕ (ꯂꯤꯅꯄꯥꯔꯖꯥ) ꯑꯃꯁꯨꯡ ꯇꯥꯂꯥꯖꯣꯄꯥꯔꯤꯕ (ꯇꯥꯂꯖꯦꯟꯅꯥ) ꯒꯨꯝꯕꯥ ꯗ꯭ꯔꯒꯁꯤꯡ ꯑꯁꯤ ꯕꯤ.ꯑꯥꯔ.ꯁꯤ.ꯑꯦ.ꯒꯤ ꯖꯤꯟ ꯃ꯭ꯌꯨꯇꯦꯁꯟ ꯂꯩꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯗꯥ ꯁꯤꯖꯤꯟꯅꯩ꯫ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡꯅꯥ ꯃꯁꯥ ꯃꯊꯟꯇꯥ ꯁꯦꯃꯖꯕꯥ ꯉꯝꯕꯒꯤ ꯁꯛꯇꯤ ꯑꯗꯨ ꯊꯤꯡꯏ꯫
  • ꯏꯝꯝꯌꯨꯅꯣꯊꯦꯔꯥꯄꯤ: ꯑꯦꯇꯦꯖꯣꯂꯤꯖꯨꯃꯕ (ꯇꯦꯁꯦꯟꯠꯔꯤꯛ) ꯒꯨꯝꯕꯥ ꯗ꯭ꯔꯒꯁꯤꯡꯅꯥ ꯑꯩꯈꯣꯌꯒꯤ ꯏꯁꯥꯒꯤ ꯏꯝꯝꯌꯨꯟ ꯁꯦꯂꯁꯤꯡ ꯁꯤꯖꯤꯟꯅꯗꯨꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡꯒꯥ ꯂꯥꯟꯊꯦꯡꯅꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫

ꯃꯁꯤ ꯄꯨꯝꯅꯃꯛ ꯑꯁꯤ ꯈꯔꯥ ꯍꯦꯟꯅꯥ ꯂꯨꯝꯅꯥ ꯂꯧꯕꯥ ꯌꯥꯏ꯫ ꯃꯗꯨ ꯅꯣꯔꯃꯦꯂꯅꯤ꯫ ꯃꯔꯨ ꯑꯣꯏꯕꯥ ꯋꯥꯐꯃꯗꯤ ꯅꯍꯥꯛꯅꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯃꯈꯜ ꯑꯃꯠꯇꯒꯤ ꯀꯦꯟꯁꯔ ꯂꯩꯔꯕꯁꯨ, ꯃꯁꯤꯒꯤꯗꯃꯛꯇꯥ ꯆꯨꯅꯕꯥ ꯂꯥꯌꯦꯡꯁꯤꯡ ꯉꯁꯤꯗꯤ ꯐꯪꯂꯤ ꯍꯥꯌꯕꯥ ꯅꯤꯡꯁꯤꯡꯕꯥ ꯑꯁꯤꯅꯤ꯫ ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔ ꯑꯃꯁꯨꯡ ꯃꯦꯗꯤꯀꯦꯜ ꯇꯤꯃꯅꯥ ꯅꯍꯥꯛꯀꯤꯗꯃꯛꯇꯥ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯐꯕꯥ ꯂꯥꯏꯌꯦꯡꯒꯤ ꯄ꯭ꯂꯥꯟ ꯁꯦꯝꯅꯕꯥ ꯅꯍꯥꯛꯀꯥ ꯂꯣꯌꯅꯅꯥ ꯊꯕꯛ ꯇꯧꯃꯤꯟꯅꯒꯅꯤ꯫

ꯇꯦꯛ-ꯍꯣꯝ ꯃꯦꯁꯦꯖ ꯇꯧꯕꯥ꯫

  • ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯑꯁꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯜ 3ꯗꯥ ꯈꯥꯌꯗꯣꯀꯏ: ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ-ꯄꯣꯖꯤꯇꯤꯚ, HER2-ꯄꯣꯖꯤꯇꯤꯚ, ꯑꯃꯁꯨꯡ ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯚ .
  • ꯅꯍꯥꯛꯅꯥ ꯀꯔꯤ ꯃꯈꯂꯒꯤ ꯀꯦꯟꯁꯔ ꯂꯩꯕꯒꯦ ꯍꯥꯌꯕꯗꯨ ꯈꯪꯖꯤꯅꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯂꯥꯏꯌꯦꯡꯕꯒꯤ ꯊꯧꯔꯥꯡ ꯇꯧꯕꯗꯥ ꯌꯥꯝꯅꯥ ꯃꯔꯨꯑꯣꯏ꯫
  • ꯍꯣꯔꯃꯣꯟ-ꯄꯣꯖꯤꯇꯤꯚ ꯀꯦꯟꯁꯔꯁꯤꯡꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤꯗꯥ ꯐꯖꯅꯥ ꯔꯦꯁꯄꯣꯟꯁ ꯇꯧꯏ꯫
  • HER2-ꯄꯣꯖꯤꯇꯤꯕ ꯀꯦꯟꯁꯔꯁꯤꯡ ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯊꯨꯅꯥ ꯍꯦꯅꯒꯠꯂꯛꯂꯕꯁꯨ, ꯃꯈꯣꯌꯒꯤꯗꯃꯛꯇꯥ ꯑꯈꯟꯅꯅꯥ ꯁꯦꯃꯒꯠꯄꯥ ꯌꯥꯝꯅꯥ ꯏꯐꯦꯛꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯇꯥꯔꯒꯦꯠ ꯇꯧꯔꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ ꯂꯩꯔꯤ꯫
  • ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ ꯀꯦꯟꯁꯔ ꯂꯥꯌꯦꯡꯕꯗꯥ ꯁꯤꯡꯅꯕꯥ ꯑꯃꯥ ꯑꯣꯏꯔꯕꯁꯨ, ꯃꯈꯣꯌ ꯑꯁꯤ ꯀꯦꯃꯣꯊꯦꯔꯥꯄꯤ ꯑꯃꯁꯨꯡ ꯑꯅꯧꯕꯥ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯂꯥꯟꯊꯦꯡꯅꯕꯥ ꯌꯥꯏ꯫
  • ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯀꯤ ꯃꯦꯗꯤꯀꯦꯜ ꯔꯦꯀꯣꯔꯗꯇꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯃꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯋꯥꯍꯪ ꯑꯃꯠꯇꯥ ꯂꯩꯔꯕꯗꯤ, ꯍꯪꯕꯗꯥ ꯋꯥꯈꯜ ꯋꯥꯕꯥ ꯂꯩꯔꯣꯏꯗꯕꯅꯤ . ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯗꯥ ꯃꯌꯦꯛ ꯁꯦꯡꯕꯥ ꯄꯥꯎꯈꯨꯝ ꯑꯃꯥ ꯄꯤꯌꯨ꯫ ꯑꯗꯣꯝ ꯈꯛꯇꯒꯤ ꯅꯠꯇꯦ, ꯑꯗꯣꯃꯕꯨ ꯃꯇꯦꯡ ꯄꯥꯡꯕꯥ ꯉꯝꯕꯥ ꯃꯤꯑꯣꯏ ꯀꯌꯥꯁꯨ ꯂꯩꯔꯤ꯫

ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ, ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ, ꯀꯦꯟꯁꯔ ꯃꯈꯂꯁꯤꯡ, ꯍꯣꯔꯃꯣꯟ-ꯄꯣꯖꯤꯇꯤꯕ, HER2-ꯄꯣꯖꯤꯇꯤꯕ, ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ, ꯀꯦꯟꯁꯔ ꯂꯥꯌꯦꯡ, ꯅꯨꯄꯤꯒꯤ ꯍꯀꯁꯦꯜ꯫
⚠️ Important: The medical articles and information on Nirogi Lanka are for general awareness only, and are by no means a substitute for professional medical advice, diagnosis, or treatment. For any medical problem you have, consult a qualified physician immediately.

💬 Comments (0)

No comments yet. Be the first to share your thoughts here.

Add Your Comment

Please calculate: 3 + 2 =
ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯌꯔꯒꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯂꯁꯤꯡ ꯑꯗꯨ ꯀꯔꯤꯅꯣ? (ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔꯒꯤ ꯃꯈꯂꯁꯤꯡ) ꯃꯁꯤ ꯌꯥꯝꯅꯥ ꯂꯥꯏꯅꯥ ꯂꯧꯁꯤ꯫
ꯅꯨꯄꯤꯁꯤꯡꯒꯤ ꯍꯀꯁꯦꯜ꯫জুলাই ৬, ২০২৬

ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯌꯔꯒꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯂꯁꯤꯡ ꯑꯗꯨ ꯀꯔꯤꯅꯣ? (ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔꯒꯤ ꯃꯈꯂꯁꯤꯡ) ꯃꯁꯤ ꯌꯥꯝꯅꯥ ꯂꯥꯏꯅꯥ ꯂꯧꯁꯤ꯫

ꯅꯍꯥꯛꯅꯥ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯂꯩꯔꯦ ꯍꯥꯌꯕꯥ ꯈꯪꯂꯕꯥ ꯃꯇꯃꯗꯥ ꯅꯍꯥꯛꯅꯥ ꯐꯥꯎꯔꯤꯕꯥ ꯑꯀꯤꯕꯥ ꯑꯃꯁꯨꯡ ꯁꯣꯀꯄꯥ ꯑꯗꯨ ꯋꯥꯍꯩꯅꯥ ꯐꯣꯡꯗꯣꯀꯄꯥ ꯌꯥꯝꯅꯥ ꯂꯨꯏ꯫ ꯑꯗꯣꯃꯒꯤ ꯋꯥꯈꯂꯗꯥ ꯋꯥꯍꯪ ꯀꯌꯥ ꯑꯃꯥ ꯂꯩꯔꯤ꯫ "ꯑꯩꯉꯣꯟꯗꯥ ꯀꯔꯤꯒꯤ ꯊꯣꯀꯈꯤꯕꯅꯣ?", "ꯍꯧꯖꯤꯛ ꯑꯩꯅꯥ ꯀꯔꯤ ꯇꯧꯔꯤꯕꯅꯣ?", "ꯃꯁꯤ ꯂꯥꯌꯦꯡꯕꯥ ꯉꯃꯒꯗ꯭ꯔꯥ?", ꯑꯁꯤꯒꯨꯝꯕꯥ ꯋꯥꯍꯪꯁꯤꯡ ꯑꯁꯤ ꯅꯣꯔꯃꯦꯂꯅꯤ꯫ ꯈꯣꯡꯆꯠ ꯑꯁꯤꯗꯥ ꯑꯩꯍꯥꯛꯅꯥ ꯋꯥꯐꯃꯁꯤꯡ ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯂꯥꯏꯅꯥ ꯑꯃꯁꯨꯡ ꯑꯗꯣꯝꯅꯥ ꯈꯉꯕꯥ ꯉꯝꯕꯥ ꯂꯣꯜ ꯑꯃꯗꯥ ꯐꯣꯡꯗꯣꯛꯅꯕꯥ ꯍꯣꯠꯅꯔꯤ꯫ ꯅꯍꯥꯛꯅꯥ ꯀꯔꯤ ꯃꯈꯂꯒꯤ ꯀꯦꯟꯁꯔ ꯂꯩꯕꯒꯦ ꯍꯥꯌꯕꯗꯨ ꯆꯨꯝꯅꯥ ꯈꯉꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯂꯥꯟ ꯍꯧꯗ꯭ꯔꯤꯉꯩꯒꯤ ꯃꯃꯥꯡꯗꯥ ꯌꯦꯛꯅꯕꯥ ꯑꯗꯨꯕꯨ ꯈꯉꯕꯒꯥ ꯃꯥꯟꯅꯩ꯫ ꯃꯗꯨ ꯅꯍꯥꯛꯀꯤꯗꯃꯛꯇꯥ ꯆꯨꯅꯕꯥ ꯂꯥꯏꯌꯦꯡ ꯈꯅꯕꯒꯤ ꯑꯍꯥꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯈꯣꯡꯊꯥꯡꯅꯤ꯫

ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ-ꯄꯣꯖꯤꯇꯤꯚ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ꯫

ꯃꯁꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯀꯃꯟ ꯑꯣꯏꯕꯥ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯃꯈꯜꯅꯤ꯫ ꯆꯥꯎꯔꯥꯛꯅꯥ ꯍꯥꯌꯔꯕꯗꯥ, ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ 100 ꯈꯨꯗꯤꯡꯒꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 80ꯗꯤ ꯀꯦꯇꯦꯒꯣꯔꯤ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡ ꯆꯜꯂꯤ꯫

ꯑꯗꯨꯅꯥ ꯃꯁꯤꯒꯤ "ꯍꯣꯔꯃꯣꯟ-ꯗꯤꯄꯦꯟꯗꯦꯟꯇ" ꯍꯥꯌꯕꯁꯤ ꯀꯔꯤꯅꯣ?

ꯃꯁꯤꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯁꯨꯞꯅꯇꯒꯤ ꯈꯟꯊꯕꯤꯌꯨ꯫ ꯑꯩꯈꯣꯌꯒꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯃꯔꯨꯑꯣꯏꯅꯥ ꯅꯨꯄꯤꯁꯤꯡꯒꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯃꯍꯧꯁꯥꯅꯥ ꯊꯣꯀꯄꯥ ꯍꯣꯔꯃꯣꯟ ꯑꯅꯤ ꯂꯩ, ꯃꯈꯣꯌꯁꯤꯡ ꯑꯗꯨꯗꯤ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯑꯃꯁꯨꯡ ꯄ꯭ꯔꯣꯖꯦꯁ꯭ꯇꯦꯔꯣꯟ . ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤ ꯑꯩꯈꯣꯌꯒꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯅꯣꯔꯃꯦꯜ ꯑꯣꯏꯕꯥ ꯊꯧꯑꯣꯡꯁꯤꯡꯒꯤꯗꯃꯛ ꯇꯉꯥꯏ ꯐꯗꯕꯁꯤꯡꯅꯤ꯫ ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯈꯔꯗꯤ ꯍꯣꯔꯃꯣꯅꯁꯤꯡ ꯑꯁꯤꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯌꯥꯝꯅꯥ "ꯑꯦꯗꯤꯛꯇ" ꯑꯣꯏ꯫ ꯍꯥꯌꯕꯗꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯁꯤꯒꯤ ꯃꯊꯛꯇꯥ, ꯍꯣꯔꯃꯣꯅꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯂꯥꯛꯇꯨꯅꯥ ꯂꯦꯞꯄꯥ ꯌꯥꯕꯥ "ꯔꯤꯁꯦꯄꯇꯔ" ꯅꯠꯠꯔꯒꯥ ꯊꯣꯡ ꯈꯔꯥ ꯂꯩ꯫ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯍꯣꯔꯃꯣꯟ ꯂꯥꯛꯇꯨꯅꯥ ꯊꯣꯡ ꯑꯗꯨꯗꯥ ꯊꯨꯒꯥꯌꯕꯥ ꯃꯇꯃꯗꯥ, ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯑꯗꯨꯅꯥ ꯃꯗꯨꯗꯒꯤ ꯃꯆꯤꯟꯖꯥꯛ ꯐꯪꯏ ꯑꯃꯁꯨꯡ ꯆꯥꯎꯈꯠꯄꯥ ꯑꯃꯁꯨꯡ ꯈꯥꯌꯗꯣꯀꯄꯥ ꯍꯧꯏ꯫ ꯄꯥꯝꯕꯤ ꯑꯃꯗꯥ ꯏꯁꯤꯡ ꯄꯤꯖꯕꯥ ꯃꯇꯃꯗꯥ ꯃꯗꯨꯁꯨ ꯍꯦꯟꯅꯥ ꯆꯥꯎꯈꯠꯂꯀꯏ꯫

ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯀꯤ ꯃꯦꯗꯤꯀꯦꯜ ꯔꯤꯄꯣꯔꯠ ꯑꯗꯨꯗꯥ `ER-positive` (Estrogen Receptor-Positive) ꯍꯥꯌꯔꯕꯗꯤ, ꯃꯁꯤꯅꯥ ꯅꯍꯥꯛꯀꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯗꯨ ꯍꯣꯔꯃꯣꯟ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯅꯗꯥ ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯣꯏ ꯍꯥꯌꯕꯅꯤ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯃꯁꯤꯅꯥ `PR-positive` (Progesterone Receptor-Positive) ꯍꯥꯌꯔꯕꯗꯤ, ꯃꯁꯤꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯄ꯭ꯔꯣꯖꯦꯁ꯭ꯇꯦꯔꯣꯅꯗꯥ ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯣꯏ ꯍꯥꯌꯕꯅꯤ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯃꯁꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯑꯃꯗꯥ ꯁꯦꯟꯁꯤꯇꯤꯚ ꯑꯣꯏꯔꯕꯗꯤ, ꯀꯦꯟꯁꯔ ꯑꯗꯨꯕꯨ ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯞꯇꯔ-ꯄꯣꯖꯤꯇꯤꯚ ꯀꯦꯟꯁꯔ ꯍꯥꯌꯅꯥ ꯀꯧꯏ꯫

ꯃꯁꯤ ꯇꯁꯦꯡꯅꯥ ꯃꯑꯣꯡ ꯑꯃꯗꯥ ꯑꯐꯕꯥ ꯄꯥꯎꯅꯤ꯫ ꯃꯔꯃꯗꯤ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯩꯈꯣꯌꯅꯥ ꯀꯦꯟꯁꯔꯅꯥ ꯆꯥꯎꯈꯠꯄꯗꯥ ꯀꯔꯤ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯒꯦ ꯍꯥꯌꯕꯥ ꯈꯉꯂꯕꯗꯤ ꯑꯩꯈꯣꯌꯅꯥ ꯂꯝꯕꯤ ꯑꯗꯨ ꯕ꯭ꯂꯣꯛ ꯇꯧꯕꯥ ꯉꯃꯒꯅꯤ ꯑꯃꯁꯨꯡ ꯀꯦꯟꯁꯔ ꯑꯗꯨ ꯀꯟꯠꯔꯣꯜ ꯇꯧꯕꯥ ꯉꯃꯒꯅꯤ꯫ "ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤ" ꯍꯥꯌꯕꯁꯤ ꯃꯗꯨꯒꯤꯗꯃꯛꯇꯅꯤ꯫

ꯃꯍꯧꯁꯥꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤ ꯑꯁꯤ ꯁꯔꯖꯔꯤ, ꯀꯦꯃꯣꯊꯦꯔꯥꯄꯤ ꯅꯠꯠꯔꯒꯥ ꯔꯦꯗꯤꯑꯦꯁꯅꯒꯤ ꯃꯇꯨꯡꯗꯥ ꯀꯦꯟꯁꯔ ꯑꯗꯨ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯂꯥꯀꯄꯥ ꯊꯤꯡꯅꯕꯥ ꯄꯤ꯫ ꯍꯤꯗꯥꯀꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡꯗꯥ "ꯊꯣꯡ" ꯊꯤꯡꯗꯨꯅꯥ, ꯅꯠꯠꯔꯒꯥ ꯍꯀꯆꯥꯡꯅꯥ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯁꯦꯝꯕꯥ ꯊꯤꯡꯗꯨꯅꯥ ꯊꯕꯛ ꯇꯧꯏ꯫

ꯂꯥꯏꯌꯦꯡꯕꯒꯤ ꯀꯦꯇꯦꯒꯣꯔꯤ꯫ꯏꯆꯝ ꯆꯝꯕꯥ ꯃꯌꯦꯛ ꯁꯦꯡꯅꯥ ꯇꯥꯀꯄꯥ ꯑꯃꯁꯨꯡ ꯈꯨꯗꯃꯁꯤꯡ꯫
ꯑꯦꯁ.ꯏ.ꯑꯥꯔ.ꯑꯦꯝ.ꯁꯤꯡ (ꯁꯦꯂꯦꯛꯇꯤꯕ ꯏ.ꯑꯥꯔ. ꯃꯣꯗ꯭ꯌꯨꯂꯦꯇꯔꯁꯤꯡ) ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯗꯥ ꯂꯩꯕꯥ ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯗꯨ ꯕ꯭ꯂꯣꯛ ꯇꯧꯗꯨꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯑꯗꯨ ꯆꯪꯂꯀꯄꯥ ꯊꯤꯡꯏ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ, ꯇꯥꯃꯣꯛꯁꯤꯐꯦꯟ, ꯇꯣꯔꯦꯃꯤꯐꯦꯟ .
ꯑꯦꯁ.ꯏ.ꯑꯥꯔ.ꯗꯤ.ꯁꯤꯡ (ꯁꯦꯂꯦꯛꯇꯤꯕ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯔꯤꯁꯦꯄꯇꯔ ꯗꯤꯒ꯭ꯔꯦꯗꯔꯁꯤꯡ) ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯗꯨ ꯕ꯭ꯂꯣꯛ ꯇꯧꯕꯇꯥ ꯅꯠꯇꯅꯥ ꯃꯗꯨꯁꯨ ꯃꯥꯡꯍꯜꯂꯤ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯐꯨꯂꯚꯦꯁ꯭ꯠꯔꯦꯟꯇ (ꯐꯥꯁꯂꯣꯗꯦꯛꯁ), ꯏꯂꯥꯁꯦꯁ꯭ꯠꯔꯦꯟꯇ (ꯑꯣꯔꯁꯦꯔꯗꯨ) .
ꯑꯦꯔꯣꯃꯥꯇꯦꯖ ꯏꯅꯍꯤꯕꯤꯇꯔꯁꯤꯡ꯫ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯍꯀꯆꯥꯡꯗꯥ ꯍꯣꯔꯃꯣꯟ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ (ꯑꯌꯥꯝꯕꯥ ꯃꯇꯃꯗꯥ ꯄꯣꯁ꯭ꯠ-ꯃꯦꯅꯣꯄꯣꯖꯜ ꯅꯨꯄꯤꯁꯤꯡꯗꯥ ꯄꯤꯕꯥ) ꯄꯨꯊꯣꯀꯄꯥ ꯊꯤꯡꯏ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯑꯦꯅꯥꯁ꯭ꯠꯔꯣꯖꯣꯜ (ꯑꯦꯔꯤꯃꯤꯗꯦꯛꯁ), ꯂꯦꯠꯔꯣꯖꯣꯜ (ꯐꯦꯃꯥꯔꯥ) .
ꯑꯦꯜ.ꯑꯩꯆ.ꯑꯥꯔ.ꯑꯩꯆ.ꯒꯤ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯇꯁꯤꯡ꯫ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯃꯇꯝ ꯈꯔꯒꯤ ꯑꯣꯏꯅꯥ ꯑꯣꯚꯔꯑꯣꯜ ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯄꯨꯊꯣꯀꯄꯥ ꯊꯤꯡꯏ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯒꯣꯁꯦꯔꯦꯂꯤꯟ (ꯖꯣꯂꯥꯗꯦꯛꯁ), ꯂꯤꯎꯞꯔꯣꯂꯥꯏꯗ (ꯂꯨꯞꯔꯣꯟ) .
ꯑꯇꯣꯞꯄꯥ ꯇꯥꯔꯒꯦꯠ ꯇꯧꯔꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ꯫ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤꯒꯤ ꯃꯥꯌ ꯄꯥꯀꯄꯥ ꯍꯦꯅꯒꯠꯍꯅꯕꯥ ꯑꯇꯣꯞꯄꯥ ꯗ꯭ꯔꯒꯁꯤꯡ꯫ ꯈꯨꯗꯝ ꯑꯣꯏꯅꯥ: ꯄꯥꯂꯕꯣꯁꯤꯛꯂꯤꯕ (ꯏꯕ꯭ꯔꯥꯟꯁ), ꯔꯥꯏꯕꯣꯁꯤꯛꯂꯤꯕ (ꯀꯤꯁꯀꯥꯂꯤ), ꯑꯂꯄꯦꯂꯤꯁꯤꯕ (ꯄꯤꯛꯔꯦ) .

HER2-ꯄꯣꯖꯤꯇꯤꯚ ꯑꯣꯏꯕꯥ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ꯫

ꯍꯧꯖꯤꯛ ꯑꯇꯣꯞꯄꯥ ꯃꯈꯜ ꯑꯃꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯋꯥꯔꯤ ꯁꯥꯔꯁꯤ꯫ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯈꯔꯗꯤ (ꯀꯦꯟꯁꯔ ꯄꯨꯝꯅꯃꯛꯀꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 20%)ꯅꯥ ꯃꯈꯣꯌꯒꯤ ꯃꯊꯛꯇꯥ HER2 (Human Epidermal growth factor Receptor 2) ꯀꯧꯕꯥ ꯑꯈꯟꯅꯕꯥ ꯄ꯭ꯔꯣꯇꯤꯟ ꯑꯃꯥ ꯌꯥꯝꯅꯥ ꯄꯨꯊꯣꯀꯏ꯫

HER2 ꯑꯁꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯗꯥ "ꯌꯥꯝꯅꯥ ꯌꯥꯡꯅꯥ ꯆꯥꯎꯈꯠꯄꯥ, ꯌꯥꯡꯅꯥ ꯈꯥꯌꯗꯣꯀꯄꯥ" ꯍꯥꯌꯕꯥ ꯈꯔꯥ ꯑꯦꯟꯇꯦꯅꯥ ꯑꯃꯥ ꯑꯣꯏꯅꯥ ꯈꯅꯕꯤꯌꯨ꯫ ꯅꯣꯔꯃꯦꯜ ꯁꯦꯜ ꯑꯃꯗꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯑꯦꯟꯇꯦꯅꯥꯁꯤꯡ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯈꯔꯈꯛꯇꯃꯛ ꯂꯩ꯫ ꯑꯗꯨꯕꯨ HER2 ꯄꯣꯖꯤꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯜ ꯑꯃꯗꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯑꯦꯟꯇꯦꯅꯥ ꯀꯌꯥ ꯑꯃꯥ ꯂꯩ꯫ ꯃꯔꯝ ꯑꯁꯤꯅꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯃꯈꯂꯒꯤ ꯀꯦꯟꯁꯔꯁꯤꯡ ꯑꯁꯤ ꯍꯦꯟꯅꯥ ꯑꯦꯒ꯭ꯔꯦꯁꯤꯕ ꯑꯣꯏꯕꯥ ꯌꯥꯏ .

ꯑꯗꯨꯕꯨ ꯃꯐꯝ ꯑꯁꯤꯗꯥ ꯑꯐꯕꯥ ꯄꯥꯎ ꯑꯃꯁꯨ ꯂꯩꯔꯤ꯫ ꯁꯥꯏꯟꯁꯇꯥ ꯑꯍꯣꯡꯕꯥ ꯂꯥꯀꯄꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯍꯧꯖꯤꯛꯇꯤ ꯌꯥꯝꯅꯥ HER2 ꯑꯦꯟꯇꯦꯅꯥꯁꯤꯡ ꯑꯁꯤꯕꯨ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤꯕꯥ ꯑꯃꯁꯨꯡ ꯃꯥꯡꯍꯅꯕꯥ ꯉꯝꯕꯥ "ꯇꯥꯔꯒꯦꯠ ꯇꯧꯔꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ " ꯂꯩꯔꯦ꯫ ꯃꯔꯃꯗꯤ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ HER2 ꯌꯥꯝꯅꯥ ꯂꯩꯕꯥ ꯁꯦꯂꯁꯤꯡꯈꯛꯇꯗꯥ ꯊꯤꯗꯨꯅꯥ ꯑꯦꯇꯦꯛ ꯇꯧꯏ, ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯅꯣꯔꯃꯦꯜ ꯁꯦꯂꯁꯤꯡꯗꯥ ꯑꯃꯥꯡ-ꯑꯇꯥ ꯍꯟꯊꯍꯜꯂꯤ꯫

ꯃꯁꯤꯒꯤꯗꯃꯛꯇꯥ ꯄꯤꯔꯤꯕꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯑꯃꯁꯨꯡ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯏꯐꯦꯛꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯗ꯭ꯔꯒ ꯑꯁꯤ ꯇ꯭ꯔꯥꯁ꯭ꯇꯨꯖꯨꯃꯕ (Herceptin) . ꯃꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯑꯗꯨ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯂꯥꯀꯄꯥ ꯊꯤꯡꯕꯗꯥ ꯌꯥꯝꯅꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫ ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯂꯥꯏꯌꯦꯡ ꯑꯁꯤ ꯂꯧꯕꯥ ꯃꯇꯃꯗꯥ ꯍꯥꯔꯠ ꯅꯠꯠꯔꯒꯥ ꯂꯪꯁꯇꯥ ꯏꯐꯦꯛꯇ ꯈꯔꯒꯤ ꯔꯤꯁ꯭ꯛ ꯂꯩ꯫ ꯃꯗꯨꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯋꯥꯈꯜ ꯋꯥꯕꯥ ꯂꯩꯔꯣꯏꯗꯕꯅꯤ , ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯅꯥ ꯃꯇꯝ ꯄꯨꯝꯅꯃꯛꯇꯥ ꯃꯁꯤꯒꯤꯗꯃꯛꯇꯥ ꯆꯦꯛ ꯇꯧꯒꯅꯤ꯫

ꯍꯦꯔ꯲-ꯄꯣꯖꯤꯇꯤꯕ ꯀꯦꯟꯁꯔꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯥ ꯑꯇꯣꯞꯄꯥ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ꯫
ꯄꯦꯔꯇꯨꯖꯨꯃꯕ (ꯄꯦꯔꯖꯦꯇꯥ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ. ꯑꯦꯗꯣ-ꯇ꯭ꯔꯥꯁ꯭ꯇꯨꯖꯨꯃꯕ ꯏꯃꯇꯥꯅꯁꯤꯟ (ꯀꯗꯁꯤꯂꯥ) ꯑꯁꯤ ꯑꯦꯟ.
ꯂꯥꯄꯥꯇꯤꯅꯤꯕ (ꯇꯥꯏꯀꯦꯔꯕ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ. ꯅꯦꯔꯥꯇꯤꯅꯤꯕ (ꯅꯦꯔꯂꯤꯅꯛꯁ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ.
ꯇꯨꯀꯥꯇꯤꯅꯤꯕ (ꯇꯨꯀꯤꯁꯥ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ. ꯑꯦꯅꯍꯦꯔꯇꯨ (Fam-trastuzumab deruxtecan-nxki) ꯑꯁꯤꯅꯆꯤꯡꯕꯥ (Fam-trastuzumab deruxtecan-nxki)

"ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ" ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ꯫

ꯃꯁꯤ ꯑꯍꯨꯃꯁꯨꯕꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯂꯅꯤ꯫ ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔꯒꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 10%-20%ꯗꯤ ꯃꯈꯜ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡ ꯆꯜꯂꯤ꯫ ꯀꯔꯤꯒꯤꯗꯃꯛꯇꯥ ꯃꯁꯤꯕꯨ "ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ" ꯅꯠꯔꯒꯥ "ꯇ꯭ꯔꯤꯄꯜ ꯅꯦꯒꯦꯇꯤꯕ" ꯍꯥꯌꯅꯥ ꯀꯧꯔꯤꯕꯅꯣ ꯍꯥꯌꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯈꯉꯕ꯭ꯔꯥ?

ꯃꯔꯃꯗꯤ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯁꯤꯗꯥ , .

꯱.ꯏꯁ꯭ꯠꯔꯣꯖꯦꯟ ꯔꯤꯁꯦꯄꯇꯔ (ꯏ.ꯇꯤ.ꯌꯨ.) ꯂꯩꯇꯕꯥ .

2. ꯄ꯭ꯔꯣꯖꯦꯁ꯭ꯇꯦꯔꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ (PR) ꯂꯩꯇꯕꯥ꯫

3. HER2 ꯄ꯭ꯔꯣꯇꯤꯟ ꯌꯥꯝꯅꯥ ꯂꯩꯇꯦ꯫

ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯑꯩꯈꯣꯌꯅꯥ ꯃꯃꯥꯡꯗꯥ ꯈꯟꯅꯈꯤꯕꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯄꯥꯟꯗꯝ ꯑꯍꯨꯝ ꯑꯁꯤ ꯂꯩꯇꯕꯅꯥ ꯃꯔꯝ ꯑꯣꯏꯗꯨꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤ ꯅꯠꯔꯒꯥ ꯍꯔꯁꯦꯞꯇꯤꯅꯒꯨꯝꯕꯥ HER2-ꯇꯥꯔꯒꯦꯠ ꯇꯧꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡꯅꯥ ꯃꯈꯣꯌꯗꯥ ꯊꯕꯛ ꯇꯧꯗꯦ꯫ ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯃꯈꯣꯌꯕꯨ ꯂꯥꯌꯦꯡꯕꯗꯥ ꯈꯔꯥ ꯁꯤꯡꯅꯕꯥ ꯑꯃꯥ ꯑꯣꯏꯕꯥ ꯌꯥꯏ꯫

ꯀꯦꯟꯁꯔ ꯃꯈꯜ ꯑꯁꯤ ꯑꯌꯥꯝꯕꯅꯥ ꯕꯤ.ꯑꯥꯔ.ꯁꯤ.ꯑꯦ.꯱ꯅꯥ ꯊꯣꯀꯍꯜꯂꯤ꯫ꯃꯁꯤ ꯖꯤꯟ ꯑꯃꯗꯥ ꯃ꯭ꯌꯨꯇꯦꯁꯟ ꯑꯃꯒꯥ ꯃꯔꯤ ꯂꯩꯅꯩ . ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯚ ꯀꯦꯟꯁꯔ ꯂꯩꯔꯕꯗꯤ, ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯅꯥ ꯖꯦꯅꯦꯇꯤꯛ ꯇꯦꯁ꯭ꯠ ꯇꯧꯅꯕꯥ ꯄꯥꯎꯇꯥꯛ ꯄꯤꯕꯁꯨ ꯌꯥꯏ꯫

ꯃꯁꯤꯒꯤ ꯃꯈꯜ ꯑꯁꯤ ꯃꯔꯨꯑꯣꯏꯅꯥ ꯁꯔꯖꯔꯤ, ꯀꯦꯃꯣꯊꯦꯔꯥꯄꯤ, ꯑꯃꯁꯨꯡ ꯔꯦꯗꯤꯑꯦꯁꯅꯅꯥ ꯂꯥꯌꯦꯡꯏ . ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯍꯧꯖꯤꯛꯇꯤ ꯃꯈꯜ ꯑꯁꯤꯒꯤ ꯑꯀꯛꯅꯕꯥ ꯑꯅꯧꯕꯥ ꯂꯥꯌꯦꯡꯁꯤꯡ ꯂꯩꯔꯦ꯫

  • ꯄꯤ.ꯑꯦ.ꯑꯥꯔ.ꯄꯤ.ꯒꯤ ꯏꯅꯍꯤꯕꯤꯇꯔꯁꯤꯡ: ꯑꯣꯂꯥꯄꯥꯔꯤꯕ (ꯂꯤꯅꯄꯥꯔꯖꯥ) ꯑꯃꯁꯨꯡ ꯇꯥꯂꯥꯖꯣꯄꯥꯔꯤꯕ (ꯇꯥꯂꯖꯦꯟꯅꯥ) ꯒꯨꯝꯕꯥ ꯗ꯭ꯔꯒꯁꯤꯡ ꯑꯁꯤ ꯕꯤ.ꯑꯥꯔ.ꯁꯤ.ꯑꯦ.ꯒꯤ ꯖꯤꯟ ꯃ꯭ꯌꯨꯇꯦꯁꯟ ꯂꯩꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯗꯥ ꯁꯤꯖꯤꯟꯅꯩ꯫ ꯍꯥꯌꯔꯤꯕꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡꯅꯥ ꯃꯁꯥ ꯃꯊꯟꯇꯥ ꯁꯦꯃꯖꯕꯥ ꯉꯝꯕꯒꯤ ꯁꯛꯇꯤ ꯑꯗꯨ ꯊꯤꯡꯏ꯫
  • ꯏꯝꯝꯌꯨꯅꯣꯊꯦꯔꯥꯄꯤ: ꯑꯦꯇꯦꯖꯣꯂꯤꯖꯨꯃꯕ (ꯇꯦꯁꯦꯟꯠꯔꯤꯛ) ꯒꯨꯝꯕꯥ ꯗ꯭ꯔꯒꯁꯤꯡꯅꯥ ꯑꯩꯈꯣꯌꯒꯤ ꯏꯁꯥꯒꯤ ꯏꯝꯝꯌꯨꯟ ꯁꯦꯂꯁꯤꯡ ꯁꯤꯖꯤꯟꯅꯗꯨꯅꯥ ꯀꯦꯟꯁꯔ ꯁꯦꯂꯁꯤꯡꯒꯥ ꯂꯥꯟꯊꯦꯡꯅꯕꯗꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫

ꯃꯁꯤ ꯄꯨꯝꯅꯃꯛ ꯑꯁꯤ ꯈꯔꯥ ꯍꯦꯟꯅꯥ ꯂꯨꯝꯅꯥ ꯂꯧꯕꯥ ꯌꯥꯏ꯫ ꯃꯗꯨ ꯅꯣꯔꯃꯦꯂꯅꯤ꯫ ꯃꯔꯨ ꯑꯣꯏꯕꯥ ꯋꯥꯐꯃꯗꯤ ꯅꯍꯥꯛꯅꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯃꯈꯜ ꯑꯃꯠꯇꯒꯤ ꯀꯦꯟꯁꯔ ꯂꯩꯔꯕꯁꯨ, ꯃꯁꯤꯒꯤꯗꯃꯛꯇꯥ ꯆꯨꯅꯕꯥ ꯂꯥꯌꯦꯡꯁꯤꯡ ꯉꯁꯤꯗꯤ ꯐꯪꯂꯤ ꯍꯥꯌꯕꯥ ꯅꯤꯡꯁꯤꯡꯕꯥ ꯑꯁꯤꯅꯤ꯫ ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔ ꯑꯃꯁꯨꯡ ꯃꯦꯗꯤꯀꯦꯜ ꯇꯤꯃꯅꯥ ꯅꯍꯥꯛꯀꯤꯗꯃꯛꯇꯥ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯐꯕꯥ ꯂꯥꯏꯌꯦꯡꯒꯤ ꯄ꯭ꯂꯥꯟ ꯁꯦꯝꯅꯕꯥ ꯅꯍꯥꯛꯀꯥ ꯂꯣꯌꯅꯅꯥ ꯊꯕꯛ ꯇꯧꯃꯤꯟꯅꯒꯅꯤ꯫

ꯇꯦꯛ-ꯍꯣꯝ ꯃꯦꯁꯦꯖ ꯇꯧꯕꯥ꯫

  • ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ ꯑꯁꯤ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯈꯜ 3ꯗꯥ ꯈꯥꯌꯗꯣꯀꯏ: ꯍꯣꯔꯃꯣꯟ ꯔꯤꯁꯦꯄꯇꯔ-ꯄꯣꯖꯤꯇꯤꯚ, HER2-ꯄꯣꯖꯤꯇꯤꯚ, ꯑꯃꯁꯨꯡ ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯚ .
  • ꯅꯍꯥꯛꯅꯥ ꯀꯔꯤ ꯃꯈꯂꯒꯤ ꯀꯦꯟꯁꯔ ꯂꯩꯕꯒꯦ ꯍꯥꯌꯕꯗꯨ ꯈꯪꯖꯤꯅꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯂꯥꯏꯌꯦꯡꯕꯒꯤ ꯊꯧꯔꯥꯡ ꯇꯧꯕꯗꯥ ꯌꯥꯝꯅꯥ ꯃꯔꯨꯑꯣꯏ꯫
  • ꯍꯣꯔꯃꯣꯟ-ꯄꯣꯖꯤꯇꯤꯚ ꯀꯦꯟꯁꯔꯁꯤꯡꯅꯥ ꯍꯣꯔꯃꯣꯟ ꯊꯦꯔꯥꯄꯤꯗꯥ ꯐꯖꯅꯥ ꯔꯦꯁꯄꯣꯟꯁ ꯇꯧꯏ꯫
  • HER2-ꯄꯣꯖꯤꯇꯤꯕ ꯀꯦꯟꯁꯔꯁꯤꯡ ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯊꯨꯅꯥ ꯍꯦꯅꯒꯠꯂꯛꯂꯕꯁꯨ, ꯃꯈꯣꯌꯒꯤꯗꯃꯛꯇꯥ ꯑꯈꯟꯅꯅꯥ ꯁꯦꯃꯒꯠꯄꯥ ꯌꯥꯝꯅꯥ ꯏꯐꯦꯛꯇꯤꯕ ꯑꯣꯏꯕꯥ ꯇꯥꯔꯒꯦꯠ ꯇꯧꯔꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡ ꯂꯩꯔꯤ꯫
  • ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ ꯀꯦꯟꯁꯔ ꯂꯥꯌꯦꯡꯕꯗꯥ ꯁꯤꯡꯅꯕꯥ ꯑꯃꯥ ꯑꯣꯏꯔꯕꯁꯨ, ꯃꯈꯣꯌ ꯑꯁꯤ ꯀꯦꯃꯣꯊꯦꯔꯥꯄꯤ ꯑꯃꯁꯨꯡ ꯑꯅꯧꯕꯥ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤꯕꯥ ꯊꯦꯔꯥꯄꯤꯁꯤꯡꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯂꯥꯟꯊꯦꯡꯅꯕꯥ ꯌꯥꯏ꯫
  • ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯀꯤ ꯃꯦꯗꯤꯀꯦꯜ ꯔꯦꯀꯣꯔꯗꯇꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯃꯒꯤ ꯃꯇꯥꯡꯗꯥ ꯋꯥꯍꯪ ꯑꯃꯠꯇꯥ ꯂꯩꯔꯕꯗꯤ, ꯍꯪꯕꯗꯥ ꯋꯥꯈꯜ ꯋꯥꯕꯥ ꯂꯩꯔꯣꯏꯗꯕꯅꯤ . ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯗꯥ ꯃꯌꯦꯛ ꯁꯦꯡꯕꯥ ꯄꯥꯎꯈꯨꯝ ꯑꯃꯥ ꯄꯤꯌꯨ꯫ ꯑꯗꯣꯝ ꯈꯛꯇꯒꯤ ꯅꯠꯇꯦ, ꯑꯗꯣꯃꯕꯨ ꯃꯇꯦꯡ ꯄꯥꯡꯕꯥ ꯉꯝꯕꯥ ꯃꯤꯑꯣꯏ ꯀꯌꯥꯁꯨ ꯂꯩꯔꯤ꯫

ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ, ꯕ꯭ꯔꯦꯁ꯭ꯠ ꯀꯦꯟꯁꯔ, ꯀꯦꯟꯁꯔ ꯃꯈꯂꯁꯤꯡ, ꯍꯣꯔꯃꯣꯟ-ꯄꯣꯖꯤꯇꯤꯕ, HER2-ꯄꯣꯖꯤꯇꯤꯕ, ꯇ꯭ꯔꯤꯄꯜ-ꯅꯦꯒꯦꯇꯤꯕ, ꯀꯦꯟꯁꯔ ꯂꯥꯌꯦꯡ, ꯅꯨꯄꯤꯒꯤ ꯍꯀꯁꯦꯜ꯫
⚠️ Important: The medical articles and information on Nirogi Lanka are for general awareness only, and are by no means a substitute for professional medical advice, diagnosis, or treatment. For any medical problem you have, consult a qualified physician immediately.

💬 Comments (0)

No comments yet. Be the first to share your thoughts here.

Add Your Comment

Please calculate: 3 + 2 =